Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quaker/PepsiCo

This article was originally published in The Tan Sheet

Executive Summary

Merger completion near as FTC votes to end investigation into potential anti-competitive issues, firms announce Aug. 1. Dissenting Commissioners Sheila Anthony and Mozelle Thompson term decision "regrettable," express concerns about united Gatorade and Pepsi marketer's influence on stratified soft drink industry while Commissioners Orson Swindle and Thomas Leary note FTC can "address actual conduct" if objectionable actions are taken by new entity. PepsiCo agreed to acquire Quaker Oats in December in a deal valued at $13.4 bil. (1"The Tan Sheet" Dec. 11, 2000, p. 4)

You may also be interested in...



Functional Beverages Stimulate Natural Products Market Growth - Analysts

The natural products market, fueled by nutritionally fortified foods such as functional beverages, meal replacement bars and soy products, will continue to demonstrate strong annual growth in the mid-teens over the next several years, analysts predict.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel